Imaging single DNA molecules for high precision NIPT

Cell-free DNA analysis is becoming adopted for first line aneuploidy screening, however for most healthcare programs, cost and workflow complexity is limiting adoption of the test. We report a novel cost effective method, the Vanadis NIPT assay, designed for high precision digitally-enabled measurement of chromosomal aneuploidies in maternal plasma. Reducing NIPT assay complexity is achieved by using novel molecular probe technology that specifically label target chromosomes combined with a new readout format using a nanofilter to enrich single molecules for imaging and counting without DNA amplification, microarrays or sequencing. The primary objective of this study was to assess the Vanadis NIPT assay with respect to analytical precision and clinical feasibility. Analysis of reference DNA samples indicate that samples which are challenging to analyze with low fetal-fraction can be readily detected with a limit of detection determined at <2% fetal-fraction. In total of 286 clinical samples were analysed and 30 out of 30 pregnancies affected by trisomy 21 were classified correctly. This method has the potential to make cost effective NIPT more widely available with more women benefiting from superior detection and false positive rates.

[1]  Tak Y. Leung,et al.  Digital PCR for the molecular detection of fetal chromosomal aneuploidy , 2007, Proceedings of the National Academy of Sciences.

[2]  Tak Y. Leung,et al.  Epigenetic-Genetic Chromosome Dosage Approach for Fetal Trisomy 21 Detection Using an Autosomal Genetic Reference Marker , 2010, PloS one.

[3]  Kypros H Nicolaides,et al.  Screening for fetal aneuploidies at 11 to 13 weeks , 2011, Prenatal diagnosis.

[4]  Hanmin Lee,et al.  Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. , 2012, American journal of obstetrics and gynecology.

[5]  Janet D Cragan,et al.  Selected birth defects data from population-based birth defects surveillance programs in the United States, 2005–2009: Featuring critical congenital heart defects targeted for pulse oximetry screening. , 2012, Birth defects research. Part A, Clinical and molecular teratology.

[6]  Russell S Kirby,et al.  Selected birth defects data from population-based birth defects surveillance programs in the United States, 2006 to 2010: featuring trisomy conditions. , 2013, Birth defects research. Part A, Clinical and molecular teratology.

[7]  Amin R. Mazloom,et al.  Non-Invasive Prenatal Chromosomal Aneuploidy Testing - Clinical Experience: 100,000 Clinical Samples , 2014, PloS one.

[8]  Matthew Rabinowitz,et al.  Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. , 2014, American journal of obstetrics and gynecology.

[9]  H. Cuckle,et al.  Cell-free DNA screening for fetal aneuploidy as a clinical service. , 2015, Clinical biochemistry.

[10]  M. Halks-Miller,et al.  Noninvasive prenatal testing in the general obstetric population: clinical performance and counseling considerations in over 85 000 cases† , 2016, Prenatal diagnosis.

[11]  K. Nicolaides,et al.  Screening for trisomies by cell‐free DNA testing of maternal blood: consequences of a failed result , 2016, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[12]  Aileen Clarke,et al.  Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis , 2016, BMJ Open.

[13]  Chao Liu,et al.  Noninvasive Prenatal Screening of Fetal Aneuploidy without Massively Parallel Sequencing. , 2017, Clinical chemistry.

[14]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.